Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP)
December 24, 2025
Source: drugdu
29
Beijing Business Today — On the evening of December 22, Wantai Bio (603392.SH) announced that its wholly-owned subsidiary, Xiamen Innovax Biotech Co., Ltd., participated in the bidding for the 2025 National Immunization Program (NIP) Vaccine Centralized Procurement Project—specifically for the Bivalent Human Papillomavirus (HPV) Vaccine. The company's Bivalent HPV Vaccine (E. coli) has been shortlisted with a unit price of 27.5 RMB.
Wantai Bio stated that this centralized procurement is organized by the Chinese Center for Disease Control and Prevention (China CDC). If the company subsequently signs the procurement contract and organizes production and supply, it will help expand the sales volume of the shortlisted product, increase its market share, promote domestic market development, and enhance the company's brand influence.
https://finance.eastmoney.com/a/202512223598332095.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Over $2 billion! Another major deal for a domestically developed innovative drug December 24, 2025
- Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia December 24, 2025
- BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia December 24, 2025
- IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA December 24, 2025
- Subsidiary Receives Clinical Trial Approval for Daratumumab Injection December 24, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
